Threshold Pharmaceuticals, Inc. (THLD) is rising 6 percent to $8.93 based on the news that FDA has granted orphan drug designation for TH-302, a hypoxia-targeted drug, for treating soft tissue sarcoma.

ImmunoGen, Inc.(IMGN) is gaining 13 percent to $15.50 based on the announcement of positive results in the trastuzumab emtansine (T-DM1) EMILIA Phase III trial and the announcement of initiation of Phase II evaluation of IMGN901.

Research In Motion Ltd. (RIMM) is up nearly 2 percent to $13.97. The company announced that it is simultaneously conducting a comprehensive review of strategic opportunities. The company slipped to a loss in its fourth quarter. Both earnings per share, excluding items, and revenue were below Wall Street view.

Decliners:

Xyratex Ltd. (XRTX) is falling 9 percent to $16.10. The company's first quarter profit improved from the previous year. However, revenues declined 18 percent, and were also below consensus. The company guided second quarter results in-line with market view.

Shire plc (SHPGY) is falling more than 3 percent to $97.98. The company announced that PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis, did not meet the primary endpoint in reducing the rate of recurrence of diverticulitis over a 2-year treatment period.

Dunkin' Brands Group, Inc. (DNKN) is falling 0.33 percent to $29.96. The company announced the pricing of an upsized public offering by certain of its stockholders of 26.4 million shares of its common stock at $29.50 per share.

Finish Line Inc. (FINL) is declining 7 percent to $23.50. The company's fourth quarter non-GAAP earnings per share, matched analysts' estimate. Consolidated net sales rose 18.6 percent and were above consensus. The company guided first quarter earnings per share to be down approximately 30 percent.

Everyone knows that the Federal Reserve will raise interest rates next Wednesday at the conclusion of its two-day policy meeting.
After all, Fed speakers have been jawboning a rate hike over the past few weeks. With the markets reacting with eerie calm to Donald Trump's win, policy makers have no...

GOP strategist Karl Rove has criticized U.S. President-elect Donald Trump's comments on aircraft maker Boeing Co.'s contract for a new Air Force One plane, saying they were inaccurate and de-stabled the stock of a major company. Air Force One is the official air plane for the U.S. President.